Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
DUBLIN, April 20, 2018 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2018 on Tuesday, May 1, 2018. The Company has scheduled a conference call for that same day, Tuesday, May 1, 2018 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 |
| International: | 1-412-317-6581 |
| Conference ID #: | 10119605 |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/25538
A replay of the call can be accessed until May 8, 2018 by dialing:
| USA: | 1-877-344-7529 |
| International: | 1-412-317-0088 |
| Conference ID #: | 10119605 |
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/25538
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Contact
Kevin Tansley
Trinity Biotech plc
(353)-1-2769800
E-mail: [email protected]
Joe Diaz, Joe Dorame and Robert Blum
Lytham Partners, LLC
Investor Relations
602-889-9700
